GlassScriptPhysician profile
Steve C Tam
NPI 1285605394
$5,442.56
in general payments reported to CMS, 2019-2025
27 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $338 · 2022: $671 · 2023: $907 · 2024: $1,443 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,582 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,581.90 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $699.58 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $613.91 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Esperion Therapeutics, INC. | $591.65 | 2022-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $493.84 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $389.03 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $382.25 | 2019-2025 | Verquvo, Belsomra |
| Boston Scientific Corporation | $360.66 | 2019-2025 | Watchman Access System, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $267.99 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $251.57 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $235.33 | 2019-2025 | |
| Amarin Pharma, INC. | $210.15 | 2019-2023 | |
| Medtronic Vascular, INC. | $181.12 | 2020 | |
| Abbvie INC. | $127.58 | 2023-2025 | Viberzi, Linzess |
| Novartis Pharmaceuticals Corporation | $114.61 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $111.62 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $75.28 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.80 | 2024 | Xifaxan, Trulance |
| Azurity Pharmaceuticals, INC. | $51.96 | 2023-2024 | Edarbi, Edarbi |
| Ironwood Pharmaceuticals, INC | $43.75 | 2022-2024 | |
| Glaxosmithkline, LLC. | $37.59 | 2023-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $29.72 | 2025 | Wegovy |
| Lexicon Pharmaceuticals, INC. | $26.33 | 2024 | |
| Arbor Pharmaceuticals, INC. | $21.44 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.85 | 2020 | |
| Heartflow, INC. | $17.70 | 2024 | |
| Seqirus USA INC | $14.75 | 2024 | Fluad |
| Lilly USA, LLC | $14.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Tam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.